SLNO
Soleno Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SLNO
Soleno Therapeutics, Inc.
A clinical-stage biopharmaceutical company that currently developing a once-daily oral tablet for the treatment of Prader-Willi syndrome
Life Science Tools and Services
08/25/1999
11/13/2014
NASDAQ Stock Exchange
92
12-31
Common stock
203 Redwood Shores Parkway, Suite 500, Redwood City, California 94065
--
Soleno Therapeutics, Inc., was incorporated in Delaware on August 25, 1999. The company focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company's lead drug candidate, DCCR (diazachol) sustained-release tablets, is a potent ATP-sensitive potassium (KATP) channel activator.
Earnings Call
Q2/2025
Estimate EPS--
Actual EPS-0.09
Estimate Revenue25.14M
Actual Revenue32.70M
Soleno Therapeutics Q2 2025: Key Contradictions in Time to Fill and Revenue Growth Expectations
Aug 07,2025 03:05
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SLNO has released its 2025 Q3 earnings. EPS was reported at 0.47, versus the expected 0.06, beating expectations. The chart below visualizes how SLNO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SLNO has released its 2025 Q3 earnings report, with revenue of 66.02M, reflecting a YoY change of NaN%, and net profit of 26.01M, showing a YoY change of 133.95%. The Sankey diagram below clearly presents SLNO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
